EIPICO’s General Assembly renews confidence in Dr. Ahmed Kelani as a Chairman of the Board of Directors and The Managing Director .
March 27th, 2021
- Dr. Ahmed Kelani submitted all thanks and appreciation to all state agencies for supporting the company and in achieving its development plans and projects.
- Also appreciate and praise the company’s management and employees in the year 2020, despite the Covid-19 pandemic.
- The EPICO 3 plant project for the production of Bio medicines " Biologicals & Biosimilars " is EIPICO’s gift to Egypt.
In 2020 , Production value was 3520.9 EGP million, with a volume of 330 million packages, achieving sales of 2814.5 EGP million.
- NEIPICO achieved 5% growth in exports in 2020, while Egyptian pharmaceutical exports decreased by 5% .
The Annual meeting of the General Assembly of EIPICO Pharmaceutical Company renewed its confidence in Dr. Ahmed Kelani as Chairman and Managing Director of the company, as elected in the meeting the Board of Directors of the company, which includes Dr. Ahmed Kelani, Prof. Dr.. Hamdy El-Sayed, Prof. Dr. Adel Adawy, Prof. Atef Al-Nuqli, Prof. Dr. Maher Al-Damietta, Prof. Ahmed Laila, Prof. Dr. Fathy Ibrahim, Accountant . Fattouh Diab, Prof. Dr. Hussein Khairy, Prof. Dr. Madiha Khattab.
Dr. Ahmed Kelani expressed his thanks & gratitude to the state agencies, especially the Ministry of Health and the Egyptian Medicines Authority, supporting the company in implementing its plans and projects, and this support reflects the state’s keenness to preserve EIPICO as one of the most important strategic entities in providing medicines to the Egyptian citizen.
On the other hand, Dr. Kelani submitted the latest developments of the project to establish the EIPICO 3 factory, a huge technological leap in the field of pharmaceutical industry to Egypt, the first in Egypt and the Middle East to produce pharmaceuticals and Biologicals & Biosimilars, which will provide drugs for treating cancer and blood diseases, and Which causes great concern to the citizens and the state because of the high prices or the lack of availability sometimes, and in this context he dealt with the agreement that EIPICO is one of the largest companies in the world to produce vital medicines.
He affirmed that all the project studies have been completed, and the work in full swing ready to start the constructions, on the other hand, members of the association praised the company for entering such difficult and vital field, in the service of citizens and the national economy.
In the meeting, Dr. Kelani addressed the results of the company in FY 2020, as the company achieved production of 3520.9 EGP million, with a volume of 330 million packages, while sales amounted to 2814.5 EGP million, and EIPICO achieved exports worth LE 40, $ 09 million, with a growth rate of 5% over the year 2019, while Egyptian medicine exports decreased by 5% in 2020 due to EIPICO has maintained its leadership as the first is for Egyptian drug exports, at a rate of 23% of the total Egyptian medicine exports for the year 2020.
Dr. Ahmed Kelani announced that EIPICO is exporting to the Egyptian drug market in terms of the number of packages sold during the months of January and February of this year and according to IQVIA indicators, 7.2% of the volume of packages sold in the Egyptian drug market, achieving a growth rate of 6% over the previous year, while the growth rate of the drug market in terms of packages sold during the same period is only 2%.
Also according to IQVIA indicators, EIPICO achieved a growth in the value of its sales in the Egyptian market, which amounted to 23% of the value compared to last year, while the growth rate of the sales of the whole market was 9% compared to last year, as the company ranked sixth in the Egyptian pharmaceutical market during the months of January and February of this year, and the proportion of 3.2% of the market size.
Dr. Kelani also gave a detailed presentation on the challenges faced the company’s management and employees as well as the achievements and projects that were implemented during the year 2020, and the ongoing and future projects as well in order to develop and update all capabilities of the company in order to maintain the distinguished level of quality, and safety in its cosmetics.
The assembly's members expressed a special appreciation to the company’s management for the complete transparency in presenting and addressing the results of the company’s business, plans and projects of the company.
In conclusion, the association also expressed thanks to the leadership of the company and all employees for the performance and the projects implemented in 2020 despite Covid-19.